HURA - TuHURA Biosciences • Financials

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
06/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
06/2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	0	-30	-	0%	L	-2	L	-1	-	-12	-0	3	-13	-0	0	-	-
12/2024	0	-18	-	0%	L	14	L	-13	-	-17	-0	30	-17	0	0	-	-
12/2025	0	-32	-	0%	L	21	L	-3	-	-34	-0	20	-34	0	-0	L	-

To see all financials—including updated, you must be Premium.